Document:

Amendment to Loan and Security Agreement

 Exhibit 10.14 (a) 

February 3, 2012 

ONCOTHYREON INC. 
 2601 Fourth Avenue, Suite 500

 Seattle, Washington 98121 

Attention: Julie Eastland, Chief Financial Officer 
 Phone: (206) 801-2112 
 Facsimile: (206) 801-2101 

 

			
	RE:	  	Loan Agreement, dated as of February 8, 2011 (as amended, restated, supplemented or modified from time to time, the “Loan Agreement”), by and among
Oncothyreon Inc. (“Borrower”), the other Loan Parties signatory thereto, the Lenders signatory thereto from time to time, and General Electric Capital Corporation (“GE Capital”), as a Lender and as agent for the
Lenders (in such capacity, the “Agent”)

 Ladies and Gentlemen: 
 All capitalized terms used in this letter agreement shall have the respective meanings given such terms in the above-referenced Loan Agreement. 

Subject to the terms and conditions hereof and in accordance with Section 10.8(b) of the Loan Agreement, notwithstanding any
provision set forth in the Loan Agreement to the contrary, the Borrower, the Agent and the Requisite Lenders hereby agree that (a) the Borrower may terminate the Small Cap Biotech Agreement and (b) Section 7.13 of the Loan Agreement
is deleted in its entirety; provided, however, that (a) at all times after the date hereof and prior to August 1, 2012, (i) the Borrower shall maintain a $50,000,000 “At-the-Market” facility with Cowen and Company,
LLC, as sales agent (“Cowen”) pursuant to (1) that certain Sales Agreement, dated as of February 3, 2012, by and between Borrower and Cowen substantially in the form attached hereto as Exhibit A, and (2) any
agreements executed in connection therewith (collectively, as the same are amended from time to time in accordance with Section 7.11 of the Loan Agreement, the “Cowen Agreement”), and (ii) the Borrower shall have the
ability to make “Placement Notices” (as such term is defined in the Cowen Agreement), under the Cowen Agreement unless the Borrower has previously requested and drawn at least $12,000,000 available under the Cowen Agreement, and
(b) all references in the Loan Agreement to “Small Cap Biotech” and “Small Cap Biotech Agreement” shall be deemed to refer to Cowen and the Cowen Agreement, respectively.  

The agreement in the immediately preceding paragraph relates solely to the Cowen Agreement, and nothing in this letter agreement is
intended (or shall be construed) as the agreement of the parties to any transaction or the waiver by the Agent or Lenders of any Default or Event of Default that may now exist or hereafter occur under the Loan Agreement or a waiver by the Agent or
Lenders of any rights or remedies of the Agent and Lenders under the Debt Documents. 
 This letter agreement shall not become
effective unless, on or before the date hereof, the Borrower (i) delivers to Agent a counterpart of this letter agreement duly executed by Borrower, the other Loan Parties, the Agent and the Requisite Lenders, and (ii) delivers to Agent a
copy of the fully-executed Cowen Agreement. 

 Borrower hereby ratifies and reaffirms each and every term, covenant and condition set forth
in each Debt Document (other than to the extent expressly set forth in this letter agreement), all effective as of the date hereof. The Borrower hereby represents and warrants to the Agent and each Lender that no Default or Event of Default has
occurred and is continuing under the Loan Agreement as of the date hereof. Borrower absolutely and unconditionally agrees to reimburse the Agent for all reasonable and documented fees, costs and expenses, including all reasonable fees and expenses
of all of its counsel, advisors and other professional and service providers, incurred in the preparation, negotiation, execution and delivery of this letter agreement or the transactions contemplated hereby. 

By signing below, Borrower acknowledges and agrees that this document is a Debt Document and that the Borrower’s failure to comply
with any term or provision of this letter agreement shall constitute an immediate Event of Default under the Loan Agreement and the Agent and the Lenders shall have the right to exercise its rights and remedies pursuant to the Loan Agreement.

 Please indicate your agreement with the terms and conditions of this letter agreement by causing it to be executed by the
appropriate party in the places provided below. This letter agreement may be executed in multiple counterparts, each of which shall constitute an original hereof, and all of which taken together shall constitute one and the same agreement. This
letter agreement shall be governed by and construed in accordance with the internal laws of the State of New York (without regard to the conflict of laws principles of such state). 

[Remainder of page intentionally blank; signature page follows] 

			
	Very truly yours,
	
	 GENERAL ELECTRIC CAPITAL CORPORATION,
 as Agent and a Lender

		
	By:	 	 /s/ Peter Gibson

	Name:	 	Peter Gibson
	Title:	 	Duly Authorized Signatory

  

			
	ACCEPTED AND AGREED TO:
	
	ONCOTHYREON INC., as Borrower
		
	By:	 	 /s/ Robert Kirkman, M.D.

		 	Name: Robert Kirkman, M.D.
		 	Title: President & CEO
	
	BIOMIRA MANAGEMENT, INC., as Guarantor
		
	By:	 	 /s/ Robert Kirkman, M.D.

		 	Name: Robert Kirkman, M.D.
		 	Title: President & CEO
	
	 PROLX PHARMACEUTICALS CORPORATION,
 as Guarantor

		
	By:	 	 /s/ Robert Kirkman, M.D.

		 	Name: Robert Kirkman, M.D.
		 	Title: President & CEO

 SIGNATURE PAGE 

 EXHIBIT A 

FORM OF COWEN SALES AGREEMENTForm of Restricted Stock Award Agreement

 Exhibit 10.2 
 RESTRICTED STOCK AWARD AGREEMENT 
 This Restricted Stock Award
Agreement (the “Agreement”) is entered into as of January 26, 2012 by and between Calavo Growers, Inc., a California corporation (“Calavo”), and the director of Calavo whose names are set forth on the signature
page of this Agreement (the “Director”). 
 RECITALS 

A. Calavo’s Board of Directors (the “Board”) has adopted the 2011 Management Incentive Plan (the
“Plan”), and Calavo’s shareholders have approved the Plan. 
 B. The Director is a non-employee director
of Calavo. The Board and Calavo’s Compensation Committee (the “Compensation Committee”) have approved the award and issuance to the Director of One Thousand (1,000) shares of Calavo’s common stock, par value $0.001
per share (“Common Stock”) upon the terms set forth in this Agreement. Each member of the Compensation Committee is (1) an “outside director” within the meaning of Section 162(m) of the Internal Revenue Code of
1986, as amended, (2) a “non-employee director” within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934, as amended, and (3) an “independent director” under applicable rules and regulations of the
Nasdaq Stock Market. 
 C. On January 19, 2012, Calavo filed with the Securities and Exchange Commission (the
“SEC”) a Registration Statement on Form S-8 that covers issuances of shares of Common Stock under the Plan. 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which hereby
are acknowledged, Calavo and the Director hereby agree as follows: 
 1. Award of Shares to the Director.
Effective as of January 26, 2012, Calavo hereby awards and issues to the Director One Thousand (1,000) shares of Common Stock, which are referred to below as the “Awarded Shares.” 

2. Vesting of the Awarded Shares; Possible Forfeiture of the Awarded Shares. 

(a) As of the date of this Agreement, all of the Awarded Shares are unvested and are not transferable by the Director. Prior to the
date that the Awarded Shares vest as described below, the Director is not entitled to sell, pledge, or otherwise transfer any of the Awarded Shares. 
 (b) On January 1, 2013, all of the Awarded Shares shall fully vest, and shall become non-forfeitable and transferable by the Director, if the Director is serving as a director of Calavo on
January 1, 2013. Except as described below in Section 2(c), if the Director’s service as a director of Calavo terminates prior to January 1, 2013, all of the Awarded Shares (1) shall automatically be forfeited, cancelled on
Calavo’s share record books, and re-conveyed to Calavo by the Director on the date of his or her termination of service without the necessity for any payment by Calavo and without the necessity of any further action by the Director, and
(2) the Director shall immediately and automatically cease to have any ownership right as to the Awarded Shares as of such service termination date. 

  
 1 

 (c) All of the Awarded Shares shall fully vest, and shall become non-forfeitable and
transferable by the Director if, prior to January 1, 2013, (1) the Director’s service as a director terminates as a result of his or her death or permanent disability (as such disability shall be determined by a physician approved by
the Board), (2) Calavo’s annual meeting of shareholders is held but the Director is not re-elected as a director at the annual meeting, or (3) a “Change of Control” defined in Section 13.1 of the Plan occurs. The
Awarded Shares shall vest and become non-forfeitable and transferable as of the date of the termination of service, annual meeting, or Change of Control that is described in the preceding sentence, as applicable. 

3. Evidence of Ownership of the Awarded Shares. 
 (a) Prior to the date that the Awarded Shares vest pursuant to Section 2 above, Calavo shall not deliver to the Director a stock certificate evidencing the Awarded Shares and Calavo shall not
otherwise deposit the Awarded Shares into a brokerage or other account for the benefit of the Director. However, Calavo shall take necessary or appropriate actions to ensure that Calavo’s transfer agent recognizes the Director as the owner of
the Awarded Shares for purposes of the dividend and voting rights described below in Section 4. 
 (b) Promptly
after the date that the Awarded Shares vest pursuant to Section 2 above, Calavo shall deliver the Awarded Shares by book or electronic entry to a brokerage or other account specified by the Director or, if requested by the Director, Calavo
shall deliver to the Director a stock certificate evidencing the Awarded Shares, which certificate shall not contain any restrictive legend. 
 4. Dividend and Voting Rights. Effective as of the date of this Agreement, the Director shall have the right to vote the Awarded Shares and to receive any dividends with respect to the
Awarded Shares that Calavo may declare on the Common Stock. However, such voting and dividend rights with respect to the Awarded Shares shall terminate if and when the Awarded Shares are forfeited upon the Director’s termination of service
prior to January 1, 2013 pursuant to Section 2 above. 
 5. Minimum Share Ownership Requirement.

 (a) If the Director owns fewer than 4,000 shares of Common Stock as of the date of this Agreement, the Director
must retain ownership of at least 600 of the Awarded Shares, once vested, until the date that the Director owns at least 4,000 shares of Common Stock. Following the date that the Director owns at least 4,000 shares of Common Stock, the Director
shall not be required to retain any of the Awarded Shares, once vested, so long as the Director at all times thereafter continues to own at least 4,000 shares of Common Stock during the period that he or she is a director of Calavo. Awarded Shares
that are owned by the Director shall be counted toward the satisfaction of the share ownership requirement that is described in this Section 5(a) and in Section 5(b) below, but shares of Common Stock that may be acquired by the Director
upon the exercise of a stock option shall not be treated as being owned by the Director for purposes of the satisfaction of the share ownership requirement until the stock option is exercised. 

  
 2 

 (b) If the Director owns at least 4,000 shares of Common Stock as of the date of this
Agreement, the Director shall not be required to retain any of the Awarded Shares, once vested, but the Director must at all times continue to own at least 4,000 shares of Common Stock during the period that he or she is a director of Calavo.

 (c) Upon the request of Calavo, the Director shall provide evidence to Calavo of the number of shares of Common Stock
that he or she owns. 
 (d) The share ownership requirement described in this Section 5 shall terminate on the date
that the Director ceases for any reason to be a director of Calavo. 
 6. Securities Law Compliance. The Director
agrees not to sell, pledge, or otherwise transfer any of the Awarded Shares or any other shares of Common Stock except in full compliance with (a) Calavo’s Insider Trading Policy and (b) all applicable federal and state securities
laws, rules, and regulations, including, without limitation, the requirement to file a Form 4 on a timely basis with the SEC pertaining to such transaction and the requirement to comply with the terms of Rule 144 under the Securities Act of 1933, as
amended. The Director also agrees not to sell, pledge, or otherwise transfer any of the Awarded Shares prior to the date that they vest pursuant to Section 2 above, and any such attempted sale, pledge, or other transfer shall be null and void.
The Director acknowledges and agrees that neither Calavo nor any of its agents has made any representation to the Director about the advisability of the Director’s retention or sale of the Awarded Shares. 

7. Section 83(b) Election. The Director acknowledges and agrees that: (1) Calavo advised the Director of his or
her right to make an election under Section 83(b) of the Internal Revenue Code of 1986, as amended, regarding the Awarded Shares within thirty days after Calavo’s grant of the Awarded Shares; (2) Calavo has made no recommendation to
the Director regarding whether the Section 83(b) election should be made; (3) it is the Director’s responsibility to consult with his or her tax advisor regarding the advisability of the Section 83(b) election; (4) the
Director is responsible for the payment of any and all federal, state and other taxes that may be imposed on the Director by reason of the grant of the Awarded Shares or the Director’s subsequent sale of the Awarded Shares; and (5) the
Director promptly shall provide Calavo with a copy of any Section 83(b) election that is made by the Director. 
 8.
Incorporation by Reference of the Plan. The Plan and all of its terms, as amended from time to time, are incorporated by reference into this Agreement. The Director acknowledges that he or she has received and reviewed a copy of the Plan.
This Agreement is not a complete restatement of all of the terms of the Plan. Calavo and the Director agree to be bound by the Plan, as amended from time to time, and agree that the terms of the Plan shall govern if and to the extent that there are
any inconsistencies between the Plan and this Agreement. 

  
 3 

 9. No Right to Continue to Serve as a Director. The Director understands that
nothing in the Plan or this Agreement gives the Director a right to continue to serve as a director of Calavo. 
 10.
Miscellaneous Provisions. 
 (a) Further Instruments. Calavo and the Director agree to execute such
further instruments and to take such further actions as may be reasonably necessary to carry out the intent of this Agreement. 

(b) Provisions Subject to Applicable Law. If any provision of this Agreement is held by a court of competent jurisdiction
to be invalid, void, or unenforceable, the remaining provisions shall nevertheless continue in full force and effect without being impaired or invalidated in any way and shall be construed in accordance with the purposes and intent of this
Agreement. 
 (c) Complete Agreement. This Agreement and the Plan constitute the complete and exclusive agreement
between Calavo and the Director with respect to the subject matter of this Agreement and replace and supersede any and all other prior written and oral agreements or statements by the parties relating to such subject matter. 

(d) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of Calavo and the Director and
their respective successors and assigns. 
 (e) Notices. Any notice required or permitted to be given to Calavo or
the Director must be in writing and shall be deemed to have been duly given (1) when delivered in person, (2) when sent by facsimile transmission (provided confirmation of facsimile transmission is obtained), (3) on the second
business day after dispatch by United States registered or certified mail (postage prepaid and return receipt requested), (4) on the next business day if transmitted by national overnight courier, or (5) on the date delivered if sent by
e-mail (provided confirmation of e-mail receipt is obtained), in each case to the address shown below such party’s signature or to such other address as the party may designate in the foregoing manner to the other party. 

(f) Amendment and Termination. This Agreement may be amended or terminated only by a writing executed by both Calavo and
the Director. 
 (g) Counterparts. This Agreement may be executed by facsimile or by e-mail transmission with the
signature page attached in PDF or other format and in two counterparts, each of which shall be deemed an original, but both of which shall constitute one and the same instrument. 

(h) Governing Law; Enforcement of this Agreement. This Agreement shall be governed by, and construed and enforced in
accordance with, the internal laws of the State of California without giving effect to such state’s conflict-of-law principles. Each party to this Agreement is entitled to bring an action for temporary or preliminary injunctive relief at any
time in any court of competent jurisdiction in order to prevent immeasurable and irreparable injury that might result from a breach of this Agreement. To the fullest extent permitted by applicable law, the unsuccessful party to any court action
regarding this Agreement shall pay to 

  
 4 

 
the prevailing party all costs and expenses, including, without limitation, reasonable attorneys’ fees, incurred in the court action by the successful party, all of which shall be included
in and as a part of the award rendered in the action. For purposes of this paragraph, attorneys’ fees shall include, without limitation, fees incurred in connection with post-judgment and post-award actions. 

IN WITNESS WHEREOF, Calavo and the Director have executed and delivered this Agreement as of the day and year first written above.

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]